Company Sonoma Pharmaceuticals, Inc.

Equities

SNOA

US83558L2043

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.1663 USD +0.73% Intraday chart for Sonoma Pharmaceuticals, Inc. +24.10% -7.82%

Business Summary

Sonoma Pharmaceuticals, Inc. is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. The Company's product offerings include Regenacyn Advanced Scar Gel, Regenacyn Plus Scar Gel, Rejuvacyn Advanced Skin Repair Cooling Mist, Pediacyn Skin Care, Microcyn, Ocucyn Eyelid and Eyelash Cleanser, Microdacyn60 Oral Care, Podiacyn Advanced Everyday Foot Care, and MicrocynAH. Regenacyn Advanced Scar Gel helps to improve the overall appearance of scars while reducing pain, itch, redness, and inflammation. Regenacyn Plus is a prescription-strength scar gel which is available as an office dispense product through dermatology practices and medical spas. Pediacyn is a pediatric dermatology and wound care product for over-the-counter use. MicrocynAH is a HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.

Number of employees: 9

Sales per Business

USD in Million2022Weight2023Weight Delta
Human Care
71.0 %
9 71.3 % 9 71.0 % +4.62%
Animal Care
18.8 %
3 25.1 % 3 18.8 % -21.11%
Service/Royalty
10.1 %
0 3.6 % 1 10.1 % +199.78%

Sales per region

USD in Million2022Weight2023Weight Delta
Europe
30.5 %
-- 4 30.5 % -
United States
25.8 %
4 30.1 % 3 25.8 % -9.96%
Asia
18.5 %
-- 2 18.5 % -
Latin America
18.0 %
2 16.6 % 2 18.0 % +13.75%
Rest of the World
7.2 %
-- 1 7.2 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 57 19-09-26
Director of Finance/CFO 53 01-12-31
Director of Finance/CFO 56 20-09-07
Chief Operating Officer 60 04-02-29

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 57 19-09-26
Director/Board Member 79 07-04-19
Director/Board Member 64 18-09-18
Director/Board Member 76 13-02-28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 15,607,433 15,364,446 ( 98.44 %) 0 98.44 %

Shareholders

NameEquities%Valuation
Citadel Securities GP LLC
0.7482 %
116,779 0.7482 % 17 167 $
100,825 0.6460 % 14 821 $
Amy Trombly
0.6407 %
100,000 0.6407 % 14 700 $
Geode Capital Management LLC
0.2292 %
35,780 0.2292 % 5 260 $
JPMorgan Securities LLC
0.2118 %
33,049 0.2118 % 4 858 $
Millennium Management LLC
0.2044 %
31,897 0.2044 % 4 689 $
HRT Financial LLC
0.1785 %
27,862 0.1785 % 4 096 $
24,315 0.1558 % 3 574 $
15,505 0.0993 % 2 279 $
Goldman Sachs & Co. LLC
0.0648 %
10,111 0.0648 % 1 486 $

Company contact information

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court Suite 150

80301, Boulder

+800 759 9305

http://www.sonomapharma.com
address Sonoma Pharmaceuticals, Inc.(SNOA)

Sales per Business

Sales per region

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1663 USD
Average target price
3.25 USD
Spread / Average Target
+1,854.30%
Consensus